HARPER COURT VENTURES — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions.
BiotechDigital HealthMedical DevicesChicago, US
Harald Steltzer(Executive Officer, Director)inPatrick Conniff(Executive Officer)inEvgeny Izmchenko(Director)Nishant Agrawal(Director)in
PartnerKarthee Madasamy· solo GP
Co-investorsAngel Physicians Fund
PsiQuantum builds fault-tolerant quantum computers using photonic qubits and semiconductor manufacturing processes.
Deep TechHardwareQuantum ComputingSemiconductorsMoreton Bay, AU
Prof. Terry Rudolph(Co-founder & Chief Architect)Dr. Pete Shadbolt(Co-founder & Chief Scientific Officer)inProf. Mark Thompson(Co-founder & Chief Technology Officer)Jeremy O'Brien(Founder)inVictor Peng(Chief Executive Officer)in
BoardSiraj Khaliq(Director)in
PartnerKarthee Madasamy· solo GP
Co-investorsBlackbird VenturesC4 VenturesCold Start VenturesFounders FundFPVIntegra Groupe+24 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.